Compare · AMGN vs COEP
AMGN vs COEP
Side-by-side comparison of Amgen Inc. (AMGN) and Coeptis Therapeutics Holdings Inc. (COEP): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AMGN and COEP operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- AMGN is the larger of the two at $184.40B, about 1806.7x COEP ($102.1M).
- Over the past year, AMGN is up 18.0% and COEP is up 87.0% - COEP leads by 69.0 points.
- COEP has been more active in the news (6 items in the past 4 weeks vs 5 for AMGN).
- AMGN has more recent analyst coverage (25 ratings vs 0 for COEP).
- Company
- Amgen Inc.
- Coeptis Therapeutics Holdings Inc.
- Price
- $341.77-1.73%
- $16.27+0.81%
- Market cap
- $184.40B
- $102.1M
- 1M return
- +5.41%
- +46.05%
- 1Y return
- +18.02%
- +87.01%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1983
- 2020
- News (4w)
- 5
- 6
- Recent ratings
- 25
- 0
Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and a strategic research and development collaboration with Neumora Therapeutics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Latest AMGN
- AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS
- AMGEN TO PRESENT AT THE GOLDMAN SACHS 47TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
- AMGEN TO PRESENT NEW DATA ACROSS RARE AUTOIMMUNE AND INFLAMMATORY DISEASES AT EULAR 2026
- AMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE
- Ember LifeSciences announces new strategic investments boosting Series A to $27M
- Director Miles Amy E was granted 665 shares, increasing direct ownership by 13% to 5,640 units (SEC Form 4)
- Director Kullman Ellen Jamison was granted 665 shares, increasing direct ownership by 5% to 14,536 units (SEC Form 4)
- Director Klotman Mary E. was granted 665 shares, increasing direct ownership by 43% to 2,211 units (SEC Form 4)
- Director Jacks Tyler was granted 665 shares, increasing direct ownership by 4% to 18,284 units (SEC Form 4)
- Director Ishrak Omar was granted 665 shares, increasing direct ownership by 10% to 7,359 units (SEC Form 4)
Latest COEP
- SEC Form EFFECT filed by Coeptis Therapeutics Holdings Inc.
- SEC Form POS AM filed by Coeptis Therapeutics Holdings Inc.
- SEC Form S-1 filed by Coeptis Therapeutics Holdings Inc.
- SEC Form 4 filed by Chief Marketing Officer Schadel Christopher Ryan
- Coeptis Therapeutics Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits
- Amendment: Coeptis Therapeutics Holdings Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- Coeptis Therapeutics Holdings Inc. filed SEC Form 8-K: Leadership Update
- Coeptis Therapeutics Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Large owner Bsg Series Cm, Llc disposed of 41,521,276 shares, closing all direct ownership in the company (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13D/A filed by Coeptis Therapeutics Holdings Inc.